Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

NCT05635708 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT05635708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05635708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 7, 2023
Completion date
October 31, 2026
Enrollment
400 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancer, non-small cell lung cancer